CTI creates new R&D (research and development) division:
This article was originally published in Clinica
Executive Summary
CTI Molecular Imaging, the Knoxville, Tennessee developer of PET equipment, has established a new division, CTI Molecular Technologies (MTI), which will focus on biomarker R&D activities. According to the company, MTI's primary goals are to discover new molecular biomarkers for a wide array of disease targets and to develop novel molecular synthesis and biological screening platforms.